Navigation Links
Derma Sciences Files S-1 Registration Statement
Date:11/16/2009

PRINCETON, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI) a specialty medical device/pharmaceutical company focused on advanced wound care, announced today that it has filed an S-1 Registration Statement to offer 1,500,000 shares of its common stock. Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM) will act as sole book-running manager for the transaction.

Along with the raise, Derma has applied to list its shares on the NASDAQ under the symbol "DSCI." To meet the exchange's price requirement, Derma will hold a special shareholders' meeting on November 23, 2009 to vote on a reverse split of the Company's stock.

Derma Sciences will use the net offering proceeds to complete the purchase of the world-wide licensing rights to Medihoney, retire debt, purchase cost savings-related equipment, fund ongoing product development initiatives, and for general working capital purposes.

For more news and information on Derma Sciences, Inc., please visit www.IRGnews.com/coi/DSCI where you can find the CEO's video, a fact sheet on the company, investor presentations, and more. You can find further information at www.dermasciences.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

The offering will be made only by means of a prospectus, copies of which may be obtained from Rodman & Renshaw, LLC, 1251 Avenue of the Americas, New York, NY 10020, or by calling 212-430-1710. An electronic copy of the prospectus is also available on the web site of the Securities and Exchange Commiss
'/>"/>

SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
2. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
3. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
4. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
7. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
8. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
9. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
10. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
11. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2010)... SAN MATEO, Calif. , Feb. 8 /PRNewswire/ ... in high quality 3D Cone Beam Imaging systems for ... G. Bateman as Director of Marketing. ,, PreXion ... to have Keith on our senior management team and ... capacity.  His extensive sales and marketing leadership, experience and ...
(Date:2/8/2010)... , Feb. 8 Savient Pharmaceuticals, ... company will release financial results for the fourth quarter ... on Thursday, February 25, 2010 . ,, ... Vice President and Chief Financial Officer, will host an ... Eastern Time on February 26, 2010 ...
(Date:2/8/2010)... Feb. 8 Sagent Pharmaceuticals, ... announced that it has received FDA approval of ... control severe hypertension.  The product will be available ... 20 mL and 200 mg per 40 mL, ... more than 70 million Americans have hypertension, or ...
Breaking Medicine Technology:PreXion, Inc. Announces Appointment of Director of Marketing 2Savient Pharmaceuticals To Hold Fourth Quarter And Year-End 2009 Results Conference Call On Friday, February 26, 2010 2Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP 2Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP 3Man Discovers Cure for Excessive Sweating 48990 1Man Discovers Cure for Excessive Sweating 48990 2Pixantrone Overview in Non Hodgkins Lymphoma to be Presented at 2009 Pan Pacific Lymphoma Conference 48985 1Brooks Instrument Completes Acquisition of Celerity 26apos 3Bs Instrumentation Division 12635 1Brooks Instrument Completes Acquisition of Celerity 26apos 3Bs Instrumentation Division 12635 2Brooks Instrument Completes Acquisition of Celerity 26apos 3Bs Instrumentation Division 12635 3
(Date:2/9/2010)... more effective in persuading young women to use birth ... according to a new study. , Researchers found that ... teen pregnancy felt more vulnerable two weeks after watching ... using birth control. , However, those who watched a ... were unmoved, and had no change in their intentions ...
(Date:2/9/2010)... NEW YORK , Feb. 9 ... Angela Glover Blackwell : ,, "Reversing the childhood obesity ... leadership Michelle Obama demonstrated today. ,, ... children attend schools loaded with chips and soda -- ... Latino children, however, that bleak food landscape extends far ...
(Date:2/9/2010)... 2010 An iPhone application created by UH ... activity around the world. Those annual rankings of ... statistics and a host of indirect indicators may ... being collected at the University of Houston provides ... application, available free from Apple,s "App Store," allows ...
(Date:2/9/2010)... type II audit is a significant achievement and differentiates ... , ... (PRWEB) February 9, 2010 ... announced that it has successfully completed a Statement on Auditing ... by McGladrey & Pullen, LLP and covered Hallmark Insights operational ...
(Date:2/9/2010)... new scientific statement , , TUESDAY, Feb. 9 (HealthDay ... to be aware that certain medications can cause ... Torsade de Pointes (TdP), says a joint scientific ... American College of Cardiology. , The rhythm disturbance ... that can cause fainting. But TdP may also ...
Breaking Medicine News(10 mins):Health News:TV drama can be more persuasive than news program, study finds 2Health News:TV drama can be more persuasive than news program, study finds 3Health News:TV drama can be more persuasive than news program, study finds 4Health News:Phone app providing real-time statistics on physical activity around the world 2Health News:Phone app providing real-time statistics on physical activity around the world 3Health News:Hallmark Insights Completes SAS 70 Type II Audit 2Health News:ICU Patients at Risk for Rare Heart Rhythm Problem 2
... following is a statement from Matthew L. Myers, ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) The Campaign for Tobacco-Free ... voting to approve legislation that gives the U.S. ... tobacco products, including the authority to crack down ...
... will Support Recently Launched Military ProgramSHORT HILLS, N.J., ... Foundation, the national, non-profit organization dedicated to finding ... improving the lives of people living with paralysis, ... $25,000 from TD Bank,s charitable giving arm, the ...
... 21 The following is a statement from ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) The ... Mikulski (D-MD) for voting Wednesday to approve legislation ... (FDA) regulatory authority over tobacco products, including the ...
... Establishes Transportation as Legislative Priority for 2009WASHINGTON, May ... rewrite the federal transportation bill this year, the ... Transportation for America coalition in releasing a blueprint ... "The Route to Reform," outlines a renewed vision ...
... percent of Americans believe that long-term services and supports ... will frankly be surprised if they are not, according ... by the American Association of Homes and Services for ... 85 percent of respondents feel that health care reform ...
... maker of the Lingraphica speech-generating device for aphasia, announces ... and light, it fits easily into a pocket or ... can take along a selection of phrases, icons, and ... the Lingraphica speech-generating device and the SmallTalk provide a ...
Other Medicine News:Health News:Sen. Patty Murray Votes to Protect America's Kids from Tobacco 2Health News:Christopher & Dana Reeve Foundation Receives $25,000 Gift from TD Bank 2Health News:Christopher & Dana Reeve Foundation Receives $25,000 Gift from TD Bank 3Health News:Sen. Barbara Mikulski Votes to Protect America's Kids from Tobacco 2Health News:APHA Joins National Coalition in Issuing Transportation Reform Blueprint 2Health News:Poll Finds Americans See Long-term Services and Supports as a Priority, Not an Option, for Health Care Reform 2Health News:Poll Finds Americans See Long-term Services and Supports as a Priority, Not an Option, for Health Care Reform 3
... Sarmiento-style PTB tibial orthosis for fractures, ... closed-cell foam at bony prominences for ... 3 modular footpiece/shoe insert systems offers ... Velcro® design fits especially well in ...
Philadelphia™ Collar - Plastazote® with plastic anterior and posterior reinforcements. Hook-and-pile closure straps. Chin cradle reduces rotation. Occipital and mandibular pieces may be int...
... The Escort hip abduction brace is a lightweight ... joint technology, the Genesis Joint. The Escort ... easy to don and doff. Superior comfort ... this brace. , ,The Escort Hip ...
... Newport® Hip Management Systems are designed and ... orthosis for your patients. Innovative new options ... is built on the most successful patented ... the adjustable clamping disk design and the ...
Medicine Products: